The stock of Capricor Therapeutics Inc (CAPR) has seen a 106.53% increase in the past week, with a 162.34% gain in the past month, and a 154.75% flourish in the past quarter. The volatility ratio for the week is 20.08%, and the volatility levels for the past 30 days are at 9.87% for CAPR. The simple moving average for the last 20 days is 118.15% for CAPR stock, with a simple moving average of 145.21% for the last 200 days.
Is It Worth Investing in Capricor Therapeutics Inc (NASDAQ: CAPR) Right Now?
The 36-month beta value for CAPR is also noteworthy at 3.94. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CAPR is 27.08M, and at present, short sellers hold a 27.79% of that float. The average trading volume of CAPR on September 30, 2024 was 1.67M shares.
CAPR) stock’s latest price update
The stock price of Capricor Therapeutics Inc (NASDAQ: CAPR) has surged by 23.92 when compared to previous closing price of 9.95, but the company has seen a 106.53% gain in its stock price over the last five trading sessions. marketbeat.com reported 2024-09-30 that Capricor Therapeutics Inc. NASDAQ: CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor’s stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year.
Analysts’ Opinion of CAPR
Many brokerage firms have already submitted their reports for CAPR stocks, with Oppenheimer repeating the rating for CAPR by listing it as a “Outperform.” The predicted price for CAPR in the upcoming period, according to Oppenheimer is $14 based on the research report published on May 17, 2024 of the current year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see CAPR reach a price target of $8. The rating they have provided for CAPR stocks is “Overweight” according to the report published on January 05th, 2024.
Ladenburg Thalmann gave a rating of “Buy” to CAPR, setting the target price at $15 in the report published on October 26th of the previous year.
CAPR Trading at 156.67% from the 50-Day Moving Average
After a stumble in the market that brought CAPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.20% of loss for the given period.
Volatility was left at 9.87%, however, over the last 30 days, the volatility rate increased by 20.08%, as shares surge +172.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +165.46% upper at present.
During the last 5 trading sessions, CAPR rose by +108.54%, which changed the moving average for the period of 200-days by +220.88% in comparison to the 20-day moving average, which settled at $6.05. In addition, Capricor Therapeutics Inc saw 152.15% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAPR starting from Nippon Shinyaku Co Ltd, who purchase 2,798,507 shares at the price of $5.36 back on Sep 20 ’24. After this action, Nippon Shinyaku Co Ltd now owns 7,090,351 shares of Capricor Therapeutics Inc, valued at $14,999,998 using the latest closing price.
Musket David B, the Director of Capricor Therapeutics Inc, purchase 410 shares at $2.75 during a trade that took place back on Oct 12 ’23, which means that Musket David B is holding 31,536 shares at $1,128 based on the most recent closing price.
Stock Fundamentals for CAPR
Current profitability levels for the company are sitting at:
- -1.1 for the present operating margin
- 0.95 for the gross margin
The net margin for Capricor Therapeutics Inc stands at -1.03. The total capital return value is set at -1.87. Equity return is now at value -392.69, with -66.31 for asset returns.
Based on Capricor Therapeutics Inc (CAPR), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -8.14. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is 0.07.
Currently, EBITDA for the company is -23.01 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 14.73. The receivables turnover for the company is 73.39for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.
Conclusion
In summary, Capricor Therapeutics Inc (CAPR) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
